The APSR shared resource has been ably led by Dr. Michelle Rudek since . The APSR has offered state-of-the-art and cost-effective analytical chemistry and clinical pharmacology services to the members of the SKCCC continuously from its inception in 1985.

The APSR provides:

1. Clinical trial and preclinical study design with a focus on critical pharmacological endpoints.
2. State-of-the-art, GLP-quality, cost-effective services to quantify anticancer drugs and metabolites in biological fluids and
3. Pharmacokinetic and pharmacodynamic data analysis and interpretation.

The APSR remains a critical component across the translational spectrum providing services in analytical method development (two manuscripts), drug discovery (three manuscripts) and preclinical studies (16 manuscripts). Additionally, the APSR continues to impact the outcomes of clinical trials (18 publications) with insight into exposure-response analysis (5 publications), which are utilized to develop follow-up trials. Due to this impact, the APC was selected as one of two funded U24 PK Centers for the Early Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories. This will allow the APSR to aid in determining the optimal drug dose and schedule in current and future cancer clinical trials.

Hours of Operations

8:30 am - 5 pm

Leadership

Director: Michelle A. Rudek, Ph.D., Pharm.D.
Lab Manager: Nicole M. Anders, M.S.